Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor
Drugs that inhibit the epidermal growth factor receptor, such as ZD1839 or C225, are being used increasingly in the treatment of solid tumours. This has led to the appearance of new secondary effects. We describe the case of a patient who presented with an acneiform eruption secondary to the adminis...
| Autores: | , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2003 |
| País: | España |
| Recursos: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/23818 |
| Acesso em linha: | https://hdl.handle.net/10171/23818 |
| Access Level: | acceso abierto |
| Palavra-chave: | Antineoplastic Agents/adverse effects Lung Neoplasms/drug therapy Adenocarcinoma/drug therapy |
| Resumo: | Drugs that inhibit the epidermal growth factor receptor, such as ZD1839 or C225, are being used increasingly in the treatment of solid tumours. This has led to the appearance of new secondary effects. We describe the case of a patient who presented with an acneiform eruption secondary to the administration of ZD1839. These lesions healed in a few days after stopping the drug |
|---|